Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sex Differences in Compound 21 Dilatory Response
NCT05576155Phase 1Completed
- Start
- Oct 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in hypertension (HTN) (2 arms). Primary endpoints: Microvascular AT2R Sensitivity Following Local Control Treatment and Microvascular AT2R Sensitivity Following Local AT1R Inhibition. Started Oct 2022; status: completed.
02
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05576155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576155.